Important Notes
| Applicants are strongly advised to read the instructions and eligibility criteria before starting an application. |
| Letters of Intent (LOI) are available on the Foundant Technologies Website. |
| Invitations to submit a full application will be sent in October 2020. You must be invited to submit a full application. |
Anticipated Timeline
| June 1, 2020 | Letter of Intent Period Opens |
| August 25, 2020 | Deadline for Letter of Intent due by 11:59 pm Eastern Time |
| October 2020 | Invitation from Scientific Advisory Committee for Full Applications |
| December 1, 2020 | Full Application Deadline due by 11:59 pm Eastern Time |
| January 2021 | Grantee Notification |
| February 2021 | Grant Start Date |
Current Partner Grant Opportunities
 |
ATS/Alpha-1 Foundation Research Grant
1 grant available |
| Target Audience: Investigators (junior or established) interested in research that is relevant to alpha-1 antitrypsin deficiency (Alpha-1) |
| The focus of this research grant is proposals that have a high likelihood to advance the understanding of Alpha-1. Applications are encouraged from faculty members at any stage of their academic career. Applicants may request up to $40,000 per year for two years for salaries, supplies, or a combination of these two. Indirect costs will not be paid to the sponsoring institution. |
| Award-specific eligibility: • Junior investigators (as defined here) or established investigators at any stage in their career • Applicants must not be current awardees of the Alpha-1 Foundation Research Program • Must meet eligibility requirements for all grants found here |
| Co-funded by the ATS Research Program and the Alpha-1 Foundation. Please visit alpha1.org for more information about our partner. |
 |
ATS/American Lung Association Research Grant
1 grant available$50,000 per year for 2 years |
| Target Audience: Investigators working at Oregon, Washington, or Idaho-based institutions interested in research relevant to lung disease, sleep, and critical care |
| The focus of this research grant is basic science and patient-oriented research investigating lung disease, sleep, and critical care. We encourage proposals that investigate the impact of wildfires on patient outcomes. Patient-oriented research is defined as research performed with human subjects (or on material of human origin such as tissues or other specimen). This area of research includes 1) disease mechanism; 2) therapeutic interventions; 3) clinical trials; and 4) the development of new technologies. Applicants may request up to $50,000/year for 2 years for salaries, supplies, or a combination of these two. Indirect costs will not be paid to the sponsoring institution. |
| Award-specific eligibility: • Junior investigators (as defined here) • Applicants must be based at Idaho, Oregon, or Washington institutions • Must meet eligibility requirements for all grants found here |
| Fully funded by the American Lung Association. Please visit lung.org for more information about our partner. |
 |
ATS/chILD Foundation Research Grant
1 grant available |
| Target Audience: Investigators (junior or established) interested in research that is relevant to Children's Insterstitial and Diffuse Lung Diseases (chILD) |
|
The focus of this research grant is to advance the understanding, diagnosis, or treatment of chILD rare diseases. Examples of chILD diseases include surfactant dysfunction disorders, disorders of lung growth or lung development, lymphocytic interstitial lung disease, follicular bronchitis, bronchiolitis obliterans, pulmonary alveolar hemorrhage, pulmonary fibrosis, lung disease associated with immune dysregulation, neuroendocrine cell hyperplasia of infancy, pulmonary interstitial glycogenosis, surfactant dysfunction disorders, pulmonary alveolar proteinosis, and other chILD diseases. Relevant research could include investigations into underlying genetics, cell biology, and molecular pathways, or new diagnostic techniques, or evaluation of existing or novel therapies. Applicants may request up to $40,000 per year for two years for salaries, supplies, or a combination of these two. Indirect costs will not be paid to the sponsoring institution. |
| Award-specific eligibility: • Junior investigators (as defined here) or established investigators at any stage in their career • Must meet eligibility requirements for all grants found here |
| Co-funded by the ATS Research Program and chILD Foundation. Please visit child-foundation.org for more information about our partner. |
 |
ATS/COPD Foundation Research Grant1 grant available$40,000 per year for 2 years |
| Target Audience: Investigators interested in research that is relevant to non-CF Bronchiectasis |
| The focus of this research grant is proposals that have a high likelihood to advance the understanding of the pathophysiology of non-CF Bronchiectasis. Applicants may request up to $40,000 per year for two years for salaries, supplies, or a combination of these two. Indirect costs will not be paid to the sponsoring institution. |
| Award-specific eligibility: • Junior investigators (as defined here) • Must meet eligibility requirements for all grants found here |
| Co-funded by the ATS and the COPD Foundation. Please visit copdfoundation.org or bronchiectasisandntminitiative.org for more information about our partner. |
 |
ATS/GSK Research Grant in Obstructive Lung Disease
1 grant available$50,000 per year for 2 years |
| Target Audience: Investigators interested in research that is relevant to obstructive lung disease |
| The focus of this research grant is proposals that advance understanding of obstructive lung disease. Applicants may request up to $50,000 per year for 2 years. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution. |
| Award-specific eligibility: • Junior investigators (as defined here) • Must meet eligibility requirements for all grants found here |
| Fully funded by GlaxoSmithKline. Please visit gsk.com for more information about our partner. |
 |
ATS/Hermansky-Pudlak Syndrome Network Research Grant
|
| Target Audience: Investigators (junior or established) interested in research focusing on Hermansky-Pudlak syndrome (HPS) pulmonary fibrosis |
| The focus of this research grant is to accelerate the discovery of innovative treatment strategies for Hermansky-Pudlak syndrome pulmonary fibrosis. Priority will be given to projects that seek to identify novel therapeutic targets or to develop ground-breaking anti-fibrotic drugs against putative molecular targets. Applicants may request up to $40,000 per year for two years for salaries, supplies, or a combination of these two. Indirect costs will not be paid to the sponsoring institution. |
| Award-specific eligibility: • Junior investigators (as defined here) or established investigators at any stage in their career • Must meet eligibility requirements for all grants found here |
| Co-funded by the ATS Research Program and Hermansky-Pudlak Syndrome Network. Please visit hpsnetwork.org for more information about our partner. |
 |
ATS/ATS Public Advisory Roundtable (PAR) Research Grant
1 grant available |
| Target Audience: Investigators interested in lung disease research that is relevant to all PAR member organizations |
|
The focus of this research grant is to fund research that is relevant to all disease areas represented by the ATS PAR member organizations. Applications should address translational research, implementation science, research in oxygen, or any research that is relevant to all PAR member organizations and is not specific to one organization or one disease state. Applicants may request up to $40,000 for one year for salaries, supplies, or a combination of these two. Indirect costs will not be paid to the sponsoring institution. |
| Award-specific eligibility: • Junior investigators (as defined here) • Must meet eligibility requirements for all grants found here |
| Co-funded by the ATS Research Program and the ATS Public Advisory Roundtable (PAR). Please visit thoracic.org/patients/par/ for more information about our partner. |
Review Process
Please note that after you submit your application it will be reviewed by Research Program staff. If there are any problems or if these guidelines have not been followed, your proposal will be un-submitted. Please make sure that you check your email after you submit your application so that any outstanding issues may be addressed as quickly as possible.
The ATS Scientific Advisory Committee (SAC) will review the applications in July 2020. The membership of the SAC is listed on the ATS Website and additional ad hoc reviewers will be invited to participate as needed. Funding decisions will be made on the basis of scientific merit, novelty, and responsiveness to the purpose of the specific grant program.
ATS Policy on Additional Grant Funding
Simultaneous submission of grants with scientific overlap is allowed, but if multiple applications are funded, then the applicant must notify the Research Program within one month of formal notification of award. A subcommittee of the SAC will assess the degree of overlap. In the case of significant scientific overlap, the applicant will have to choose between the ATS Foundation research grant and the other grant. Budgetary overlap is not allowed.
If your question is not answered in the FAQ, contact the Research Program at researchprogram@thoracic.org.
